298 related articles for article (PubMed ID: 33555117)
1. A Novel Malignant Peritoneal Mesothelioma with STRN Exon 2 and ALK Exon 20: A Case Report and Literature Review.
Miyagawa C; Takaya H; Sakai K; Nishio K; Konishi M; Minamiguchi S; Shimada T; Matsumura N
Oncologist; 2021 May; 26(5):356-361. PubMed ID: 33555117
[TBL] [Abstract][Full Text] [Related]
2. Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.
Hung YP; Dong F; Watkins JC; Nardi V; Bueno R; Dal Cin P; Godleski JJ; Crum CP; Chirieac LR
JAMA Oncol; 2018 Feb; 4(2):235-238. PubMed ID: 28910456
[TBL] [Abstract][Full Text] [Related]
3.
Bulutay P; Vatansever D; Taskiran C; Mericoz CA; Tokat F; Kapucuoglu N; Kulac I
Indian J Pathol Microbiol; 2023; 66(2):392-395. PubMed ID: 37077094
[TBL] [Abstract][Full Text] [Related]
4. Identification of a recurrent STRN/ALK fusion in thyroid carcinomas.
Pérot G; Soubeyran I; Ribeiro A; Bonhomme B; Savagner F; Boutet-Bouzamondo N; Hostein I; Bonichon F; Godbert Y; Chibon F
PLoS One; 2014; 9(1):e87170. PubMed ID: 24475247
[TBL] [Abstract][Full Text] [Related]
5. Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report.
Zeng Q; Gao H; Zhang L; Qin S; Gu Y; Chen Q
Anticancer Drugs; 2021 Sep; 32(8):890-893. PubMed ID: 34232939
[TBL] [Abstract][Full Text] [Related]
6.
Gerthofer V; Scheiter A; Lüke F; Keil F; Utpatel K; Pöhmerer LM; Seitz J; Niessen C; Ignatov A; Dietmaier W; Calvisi DF; Evert M; Ortmann O; Seitz S
JCO Precis Oncol; 2021; 5():. PubMed ID: 34568722
[No Abstract] [Full Text] [Related]
7. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer.
Kelly LM; Barila G; Liu P; Evdokimova VN; Trivedi S; Panebianco F; Gandhi M; Carty SE; Hodak SP; Luo J; Dacic S; Yu YP; Nikiforova MN; Ferris RL; Altschuler DL; Nikiforov YE
Proc Natl Acad Sci U S A; 2014 Mar; 111(11):4233-8. PubMed ID: 24613930
[TBL] [Abstract][Full Text] [Related]
8. Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion.
Nikitski AV; Rominski SL; Wankhede M; Kelly LM; Panebianco F; Barila G; Altschuler DL; Nikiforov YE
Am J Pathol; 2018 Nov; 188(11):2653-2661. PubMed ID: 30125543
[TBL] [Abstract][Full Text] [Related]
9. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE
Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630
[No Abstract] [Full Text] [Related]
10. Pediatric Mesothelioma With ALK Fusions: A Molecular and Pathologic Study of 5 Cases.
Argani P; Lian DWQ; Agaimy A; Metzler M; Wobker SE; Matoso A; Epstein JI; Sung YS; Zhang L; Antonescu CR
Am J Surg Pathol; 2021 May; 45(5):653-661. PubMed ID: 33399341
[TBL] [Abstract][Full Text] [Related]
11. Characterization of thyroid cancer driven by known and novel ALK fusions.
Panebianco F; Nikitski AV; Nikiforova MN; Kaya C; Yip L; Condello V; Wald AI; Nikiforov YE; Chiosea SI
Endocr Relat Cancer; 2019 Nov; 26(11):803-814. PubMed ID: 31539879
[TBL] [Abstract][Full Text] [Related]
12. STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report.
Zhang L; Xiao P; Meng F; Zhong D
Curr Oncol; 2022 Sep; 29(10):6749-6753. PubMed ID: 36290807
[TBL] [Abstract][Full Text] [Related]
13. Identification and Development of a Lung Adenocarcinoma PDX Model With STRN-ALK Fusion.
Ren H; Hou X; Eiken PW; Zhang J; Pierson KE; Nair AA; Davila JI; Kovarikova H; Jang JS; Johnson SH; Molina JR; Marks RS; Yang P; Yi JE; Mansfield AS; Jen J
Clin Lung Cancer; 2019 Mar; 20(2):e142-e147. PubMed ID: 30581091
[No Abstract] [Full Text] [Related]
14. Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.
Hu J; Zhang B; Yao F; Fu Y; Chen D; Li D; Du N; Lizaso A; Song J; Zhang L; Li X
Ther Adv Respir Dis; 2020; 14():1753466620935770. PubMed ID: 32600123
[No Abstract] [Full Text] [Related]
15. Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma.
Mian I; Abdullaev Z; Morrow B; Kaplan RN; Gao S; Miettinen M; Schrump DS; Zgonc V; Wei JS; Khan J; Pack S; Hassan R
J Thorac Oncol; 2020 Mar; 15(3):457-461. PubMed ID: 31783178
[TBL] [Abstract][Full Text] [Related]
16. Two Cases of Renal Cell Carcinoma Harboring a Novel STRN-ALK Fusion Gene.
Kusano H; Togashi Y; Akiba J; Moriya F; Baba K; Matsuzaki N; Yuba Y; Shiraishi Y; Kanamaru H; Kuroda N; Sakata S; Takeuchi K; Yano H
Am J Surg Pathol; 2016 Jun; 40(6):761-9. PubMed ID: 26848800
[TBL] [Abstract][Full Text] [Related]
17.
Su C; Jiang Y; Jiang W; Wang H; Liu S; Shao Y; Zhao W; Ning R; Yu Q
Onco Targets Ther; 2020; 13():12515-12519. PubMed ID: 33311990
[TBL] [Abstract][Full Text] [Related]
18. Detection of STRN-ALK fusion in thyroid nodules with indeterminate cytopathology facilitates papillary thyroid cancer diagnosis.
Jurkiewicz M; Cimic A; Murty VV; Kuo JH; Hsiao S; Fazlollahi L; Fernandes H
Diagn Cytopathol; 2021 Apr; 49(4):E146-E151. PubMed ID: 33085842
[TBL] [Abstract][Full Text] [Related]
19. Anaplastic lymphoma kinase (ALK) translocation in paediatric malignant peritoneal mesothelioma: a case report of novel ALK-related tumour spectrum.
Loharamtaweethong K; Puripat N; Aoonjai N; Sutepvarnon A; Bandidwattanawong C
Histopathology; 2016 Mar; 68(4):603-7. PubMed ID: 26179668
[TBL] [Abstract][Full Text] [Related]
20. Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy.
Lin R; Mallick AB; Wang ZX; Brown SA; Lu B; Jiang W
Diagn Pathol; 2023 Oct; 18(1):116. PubMed ID: 37865792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]